This contrasts with the efficacy of this therapy in ameliorating intestinal mucositis, cancer cachexia, and anthracycline-induced cardiotoxicity [82], which may suggest that the efficacy of IL-1 inhibition in humans may be influenced by timing, dosing, and the specific context and by the dual roles of NLRP3 inflammasome in these disorders. This evidence concerns the gene IL1B and cancer.